New COVID-19 vaccine candidate provides effective option for low- to mid-income countries
(Emory Health Sciences) Combining yeast-expression technology and a novel adjuvant formulation to produce a COVID-19 vaccine candidate is effective against SARS-COV-2 and promises to be easy to produce at large scale and cost-effective, important aspects for vaccinating people worldwide, especially in low- to middle-income countries. Results from the study, which applied lessons learned from the hepatitis b vaccine platform technology, are published online today in Science Immunology.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Allergy & Immunology | COVID-19 | Hepatitis | Hepatitis B | Hepatitis Vaccine | International Medicine & Public Health | Lessons | SARS | Science | Study | Vaccines